First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. Wu YL, Kim HR, Soo RA, Zhou Q, et al. J Thorac Oncol 2025;20:955-968.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu YL, Kim HR, Soo RA, Zhou Q, et al. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. J Thorac Oncol 2025;20:955-968.
PMID: 40024442